STD Testing for IVF Patients in Kathmandu Mandatory Pre-IVF Screening, Coordinated

Overview

In-vitro fertilization requires mandatory infectious disease screening before treatment begins. This is not optional — fertility clinics in Nepal and internationally require a complete panel before egg retrieval, embryo transfer or any IVF procedure. The screening protects the patient, the partner, the future child and the laboratory staff handling gametes and embryos.

The standard pre-IVF panel includes HIV-1/2 antibody/antigen testing, hepatitis B surface antigen (HBsAg), hepatitis C antibody, syphilis serology, chlamydia and gonorrhea NAAT, and rubella immunity. Additional tests may include HSV serology, HPV screening and other markers depending on the fertility clinic protocol and patient history.

A positive result does not automatically end IVF hopes — it changes the pathway. Many infections are treatable or manageable: chlamydia and gonorrhea with antibiotics, syphilis with penicillin, hepatitis B with monitoring or treatment. HIV-positive patients can pursue IVF with appropriate precautions and antiretroviral management. The key is knowing status before procedures begin.

This page covers what the pre-IVF panel includes, why each test matters, how positive results are managed, costs in Kathmandu, and how Thamel Clinic coordinates with fertility centers for seamless screening.

The Mandatory Pre-IVF Panel

The core pre-IVF infectious disease panel covers five categories: HIV, hepatitis B, hepatitis C, syphilis, and bacterial STDs (chlamydia and gonorrhea). Each addresses a different risk — HIV and hepatitis can transmit through gametes and to lab staff, syphilis can cause congenital infection, and chlamydia/gonorrhea can cause pelvic inflammatory disease and tubal damage affecting fertility.

HIV testing uses fourth-generation Ag/Ab assays detecting both antigen and antibody — more sensitive and earlier than antibody-only tests. Hepatitis B screening checks HBsAg (current infection) and anti-HBs (immunity from vaccination or past infection). Hepatitis C uses anti-HCV antibody with RNA confirmation if positive.

Syphilis uses treponemal and non-treponemal serology in a staged algorithm. Chlamydia and gonorrhea use NAAT on urine or swab — the most sensitive method. Rubella immunity is checked because rubella in pregnancy causes severe congenital defects; non-immune patients may need vaccination before IVF.

• HIV-1/2 Ag/Ab — fourth-generation testing
• Hepatitis B: HBsAg and anti-HBs
• Hepatitis C: anti-HCV antibody ± RNA
• Syphilis: treponemal + non-treponemal serology
• Chlamydia/gonorrhea: NAAT on urine or swab
• Rubella immunity: IgG antibody

Why Screening Matters for IVF

IVF involves handling eggs, sperm and embryos outside the body — creating infection control risks that natural conception does not. Gametes and embryos can carry infectious agents; laboratory staff handle these materials daily. Screening prevents transmission to lab personnel and identifies risks to the future child.

For the patient and partner, undiagnosed STDs can cause pelvic inflammatory disease, tubal damage, epididymitis and other complications that worsen fertility. Chlamydia is particularly dangerous — it can silently damage fallopian tubes without symptoms, and finding and treating it before IVF can improve outcomes.

For the future child, infections like syphilis, HIV, hepatitis B and rubella can cause congenital infection, birth defects or serious neonatal illness. Screening before conception allows treatment or vaccination to eliminate these risks before pregnancy begins.

• Lab staff safety: gametes and embryos handled outside body
• Patient fertility: untreated STDs cause tubal damage and worsen outcomes
• Partner health: co-infections affect both partners and treatment success
• Offspring protection: congenital infection prevention
• Treatment before IVF improves success rates
• Mandatory requirement for fertility clinic clearance

Managing Positive Results

A positive pre-IVF screening result does not automatically end fertility treatment — it changes the pathway. Chlamydia and gonorrhea are cured with antibiotics; syphilis with penicillin; hepatitis B with monitoring or antiviral therapy; HIV with antiretroviral management. The fertility clinic and STD specialist coordinate to determine when IVF can safely proceed.

HIV-positive patients can pursue IVF with appropriate precautions — sperm washing for HIV-positive male partners, antiretroviral therapy to suppress viral load, and specialized protocols to prevent transmission. The key is viral suppression before conception.

Hepatitis B positive patients need evaluation for viral load and liver function — many can proceed with monitoring, while others need treatment first. Hepatitis C is now curable with direct-acting antivirals — treatment before IVF eliminates the risk.

• Chlamydia/gonorrhea: antibiotic cure, IVF can proceed after treatment
• Syphilis: penicillin cure, proceed after treatment and titer follow-up
• Hepatitis B: monitoring or antiviral therapy, viral load assessment
• Hepatitis C: curable with direct-acting antivirals before IVF
• HIV: antiretroviral therapy, sperm washing where indicated
• Fertility clinic and STD specialist coordinate clearance

Partner Screening and Coordination

Fertility clinics typically require both partners to complete infectious disease screening — not just the patient undergoing IVF. The male partner needs HIV, hepatitis B/C, syphilis and chlamydia/gonorrhea testing because these infections can affect sperm quality, transmit to the female partner and harm the pregnancy.

Coordinated screening means both partners tested at the same facility with results delivered together — streamlining the fertility clinic paperwork and reducing delays. Thamel Clinic can arrange simultaneous testing for couples with combined reporting.

If one partner tests positive, the other partner needs evaluation — co-infections are common, and treating both partners prevents reinfection and protects the IVF process. The fertility clinic needs documented results from both partners before clearance.

• Both partners typically required to screen
• Male partner: HIV, hepatitis B/C, syphilis, CT/GC
• Simultaneous testing for couples — combined reporting
• Co-infection evaluation if one partner positive
• Fertility clinic requires documented results from both
• Coordinated timing reduces IVF delays

Costs, Timing and Confidentiality

The complete pre-IVF panel typically costs Rs. 4,000 to Rs. 8,000 depending on which tests are included — HIV Ag/Ab, hepatitis B panel, hepatitis C antibody, syphilis serology, chlamydia/gonorrhea NAAT and rubella IgG. Additional tests like HSV or HPV may add cost.

Timing matters — screening should be completed well before the IVF cycle begins, ideally 4 to 6 weeks before egg retrieval or embryo transfer. This allows time for treatment if positives are found and for the fertility clinic to process results.

Confidentiality is critical — STD results are sensitive personal health information. Results are delivered privately, fertility clinic reporting is handled discreetly, and nothing is shared without consent. Digital reports can be sent directly to the fertility clinic or provided to the patient for submission.

• Complete pre-IVF panel: Rs. 4,000–8,000
• Complete 4–6 weeks before IVF cycle for clearance time
• Confidential result delivery — private or direct to fertility clinic
• Digital reports for electronic submission
• Partner screening coordinated — combined couples panel available
• Treatment time built in for positive results

Pre-IVF STD Screening Services and Costs

Prices are indicative in NPR; confirm current rates when booking. Panel pricing may vary by fertility clinic requirements.

Related Services & Guides